ArticleGynecologic oncology reports2019
NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report.
Article in Gynecologic oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Role of NTRK Fusion Genes in the Tumor Immune Microenvironment of HPV (+/-) Cervical Cancer.Journal of medical virology · 2025Review
- NTRK rearranged spindle cell neoplasm of the uterine cervix: a rare case report and literature review.BMC women's health · 2025Review
- NTRK-rearranged spindle cell neoplasm of the female genital tract: case report and literature review.Frontiers in oncology · 2025Article
- Primary pancreas NTRK-rearranged neoplasm harboring an EVT6::NTRK3 fusion with a sclerosing epithelioid fibrosarcoma morphology: a case report and comprehensive review of the literature.Frontiers in oncology · 2025Article
- The mutual interplay between NTRK fusion genes and human papillomavirus infection in cervical cancer progression (Review).Molecular and clinical oncology · 2024Review
- Metastatic malignant peripheral nerve sheath tumor of the uterus and cervix: Diagnostic Challenges, prognostic determinants and treatment.Gynecologic oncology reports · 2024Article
- TPM3::NTRK1-rearranged uterine sarcoma: case report and literature review.International journal of clinical and experimental pathology · 2024Article
- Conservative surgical treatment with fertility preservation in a young adult withGynecologic oncology reports · 2023Article
- Adult NTRK-rearranged spindle cell neoplasms of the viscera: with an emphasis on rare locations and heterologous elements.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- EML4-NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review.Frontiers in medicine · 2022Article
- Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix.Applied immunohistochemistry & molecular morphology : AIMM · 2021Article
- Establishment and genomic characterization of a sporadic malignant peripheral nerve sheath tumor cell line.Scientific reports · 2021Article
- Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019.Frontiers in oncology · 2021Review
- A narrative review of the role of fibroblasts in the growth and development of neurogenic tumors.Annals of translational medicine · 2020Review
- [Systemic therapy of sarcomas : New biomarkers and therapeutic strategies].Der Pathologe · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
•<1% of cervical cancers are sarcomas.•Data on neurofibrosarcoma management is scarce.•Larotrectinib is approved for NTRK1 gene fusion tumors without acquired resistance.•Targeted therapy of tumor genes may expand treatment for a rare cervical sarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.